How did TGTX's Q4 earnings surprise impact its stock?

**TG Therapeutics' (TGTX) Q4 earnings surprise had a negative impact on its stock.**

1. **Missed Earnings Estimate**: TGTX's Q4 earnings fell short of expectations, with the company reporting earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This represents a significant decline from the $0.73 per share earned in the same quarter the previous year.
2. **Analyst Reaction**: Analysts at HC Wainwright & Co. responded to the earnings miss by decreasing their FY2024 earnings estimates for TG Therapeutics. This reflects a broader consensus among analysts that the company's financial performance is likely to weaken further.
3. **Stock Market Reaction**: Following the earnings release, TGTX's stock likely faced downward pressure due to the negative earnings surprise and the analysts' revised estimates. Investors may have adjusted their expectations downward, leading to a potential decline in the stock price.

In summary, TGTX's Q4 earnings surprise was disappointing, leading to a potential decline in the company's stock price as analysts adjusted their estimates downward, reflecting a more cautious outlook on the company's future earnings.